Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas H, Lao CD, Janoski De Menezes J, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Tawbi HA, et al. J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124. Online ahead of print. J Clin Oncol. 2024. PMID: 39671533
Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study.
Lopez-Olivo MA, Suarez-Almazor ME, Duhon GF, Cherry M, Lu H, Calabrese C, Altan M, Tawbi H, Meara A, Bingham CO, Diab A, Leal VB, Volk RJ. Lopez-Olivo MA, et al. Among authors: tawbi h. JMIR Cancer. 2024 Oct 25;10:e53443. doi: 10.2196/53443. JMIR Cancer. 2024. PMID: 39454185 Free PMC article.
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. Long GV, et al. Among authors: tawbi h. J Clin Oncol. 2024 Nov 20;42(33):3926-3934. doi: 10.1200/JCO.24.01125. Epub 2024 Aug 13. J Clin Oncol. 2024. PMID: 39137386 Free PMC article.
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Kim ST, et al. Among authors: tawbi ha. Nat Commun. 2024 Jul 4;15(1):5621. doi: 10.1038/s41467-024-49733-9. Nat Commun. 2024. PMID: 38965214 Free PMC article. No abstract available.
Prevention of Brain Metastases: A New Frontier.
Pellerino A, Davidson TM, Bellur SS, Ahluwalia MS, Tawbi H, Rudà R, Soffietti R. Pellerino A, et al. Among authors: tawbi h. Cancers (Basel). 2024 Jun 4;16(11):2134. doi: 10.3390/cancers16112134. Cancers (Basel). 2024. PMID: 38893253 Free PMC article. Review.
Navigating the Complexities of Brain Metastases Management.
Amouzegar A, Haig S, Kahn AM, Tawbi HA, Jones JA, Goldberg SB. Amouzegar A, et al. Among authors: tawbi ha. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433694. doi: 10.1200/EDBK_433694. Am Soc Clin Oncol Educ Book. 2024. PMID: 38781565 Free article. Review.
213 results